Can phenobarbital tablets be administered sublingually to children?

Phenobarbital Tablets Should NOT Be Given Sublingually in Children

Phenobarbital tablets are not approved for sublingual administration in children and should only be given via approved routes: oral, intramuscular (IM), or intravenous (IV). The FDA labeling explicitly specifies these routes only, with no mention of sublingual administration 1.

Why Sublingual Administration Is Not Appropriate

The FDA-approved formulations and routes for phenobarbital are clearly defined:

• Oral administration (tablets/elixir)
• Intramuscular injection (deep into large muscle, maximum 5 mL per site)
• Intravenous injection (slow administration, not exceeding 60 mg/min in adults, proportionally slower in children)

1

Sublingual administration is not mentioned anywhere in the approved labeling, which means:

• No pharmacokinetic data exists for sublingual absorption
• Bioavailability via this route is unknown
• Safety has not been established
• Dosing cannot be reliably predicted

Approved Pediatric Dosing Routes

For children requiring phenobarbital, use these evidence-based approaches:

For Seizure Control:

• Loading dose: 15-20 mg/kg IV over 10-15 minutes for status epilepticus 1
• Maintenance: 4-6 mg/kg/day orally or IV for anticonvulsant therapy 1
• Oral bioavailability is excellent (96%) in critically ill patients, making oral administration highly effective when the child can swallow 2

Route Selection Algorithm:

1. If child is conscious and can swallow safely → Use oral route (tablets or elixir)
2. If child is unconscious, seizing, or cannot take oral medications → Use IV route (preferred) or IM route
3. Never use subcutaneous route (contraindicated due to tissue irritation) 1
4. Never improvise with sublingual route (no evidence base)

Critical Safety Considerations

For Neonates:

Do not use phenobarbital sodium injection in neonates due to benzyl alcohol preservative, which has caused fatal "gasping syndrome" 1. If IV phenobarbital is required in neonates, use preservative-free formulations.

For All Pediatric Patients:

• Parenteral routes should only be used when oral administration is impossible or impractical 1
• IV administration requires careful monitoring of vital signs, respiratory function, and cardiac function with resuscitation equipment immediately available 1
• Oral administration achieves therapeutic levels reliably when the child can tolerate enteral intake

Clinical Bottom Line

There is no scientific, regulatory, or clinical justification for sublingual administration of phenobarbital tablets in children. The oral route provides excellent bioavailability when feasible, and parenteral routes (IV or IM) are available when oral administration is not possible. Attempting sublingual administration introduces unnecessary uncertainty about drug absorption, unpredictable dosing, and potential safety concerns without any demonstrated benefit.

Use only FDA-approved routes: oral (preferred when tolerated), IV (for emergencies or when oral not feasible), or IM (when IV access unavailable). 1